Journal Article
. 2017 Mar;7().
doi: 10.1038/srep45554.

A new molecular prognostic score for predicting the risk of distant metastasis in patients with HR+/HER2- early breast cancer

Gyungyub Gong 1 Mi Jeong Kwon 2 Jinil Han 3 Hee Jin Lee 1 Se Kyung Lee 4 Jeong Eon Lee 4 Seon-Heui Lee 5 Sarah Park 6 Jong-Sun Choi 6 Soo Youn Cho 7 Sei Hyun Ahn 8 Jong Won Lee 8 Sang Rae Cho 3 Youngho Moon 3 Byung-Ho Nam 9 Seok Jin Nam 4 Yoon-La Choi 7 Young Kee Shin 6 
Affiliations
  • PMID: 28350001
  •     47 References
  •     9 citations

Abstract

To make an optimal treatment decision for early stage breast cancer, it is important to identify risk of recurrence. Here, we developed and validated a new prognostic model for predicting the risk of distant metastasis in patients with pN0-N1, hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer treated with hormone therapy alone. RNA was extracted from formalin-fixed, paraffin-embedded tumor tissues and gene expression was measured by quantitative real-time reverse transcription-PCR. The relative expression of six novel prognostic genes was combined with two clinical variables (nodal status and tumor size) to calculate a risk score (BCT score). In the validation cohort treated with hormone therapy alone, the 10 year rate of distant metastasis in the high-risk group (26.3%) according to BCT score was significantly higher than that in the low-risk group (3.8%) (P < 0.001). Multivariate analysis adjusted for clinical variables revealed that BCT score is an independent predictor of distant metastasis. Moreover, the C-index estimate revealed that BCT score has a prognostic power superior to that of prognostic models based on clinicopathological parameters. The BCT score outperforms prognostic models based on traditional clinicopathological factors and predicts the risk of distant metastasis in patients with HR+/HER2- early breast cancer.

Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.
J M Harvey, G M Clark, C K Osborne, D C Allred.
J Clin Oncol, 1999 May 20; 17(5). PMID: 10334533
Highly Cited.
Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.
A S Coates, E P Winer, +6 authors, Panel Members.
Ann Oncol, 2015 May 06; 26(8). PMID: 25939896    Free PMC article.
Highly Cited.
Breast cancer adjuvant therapy: time to consider its time-dependent effects.
Ismail Jatoi, William F Anderson, Jong-Hyeon Jeong, Carol K Redmond.
J Clin Oncol, 2011 May 11; 29(17). PMID: 21555693    Free PMC article.
Biologic markers determine both the risk and the timing of recurrence in breast cancer.
Laura J Esserman, Dan H Moore, +11 authors, Christopher C Benz.
Breast Cancer Res Treat, 2011 May 21; 129(2). PMID: 21597921    Free PMC article.
PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer.
Gordon C Wishart, Elizabeth M Azzato, +5 authors, Paul D P Pharoah.
Breast Cancer Res, 2010 Jan 08; 12(1). PMID: 20053270    Free PMC article.
Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series.
Christine Desmedt, Fanny Piette, +18 authors, TRANSBIG Consortium.
Clin Cancer Res, 2007 Jun 05; 13(11). PMID: 17545524
Highly Cited.
Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.
Mitch Dowsett, Ivana Sestak, +7 authors, Jack Cuzick.
J Clin Oncol, 2013 Jul 03; 31(22). PMID: 23816962
Highly Cited.
Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors.
F E Harrell, K L Lee, D B Mark.
Stat Med, 1996 Feb 28; 15(4). PMID: 8668867
Highly Cited. Review.
Clinical utility of the 70-gene MammaPrint profile in a Japanese population.
Makoto Ishitobi, Teodora E Goranova, +7 authors, Kikuya Kato.
Jpn J Clin Oncol, 2010 Jan 30; 40(6). PMID: 20110242
Supervised risk predictor of breast cancer based on intrinsic subtypes.
Joel S Parker, Michael Mullins, +17 authors, Philip S Bernard.
J Clin Oncol, 2009 Feb 11; 27(8). PMID: 19204204    Free PMC article.
Highly Cited.
Integrative investigation on breast cancer in ER, PR and HER2-defined subgroups using mRNA and miRNA expression profiling.
Xiaofeng Dai, Ana Chen, Zhonghu Bai.
Sci Rep, 2014 Oct 24; 4. PMID: 25338681    Free PMC article.
Molecular portraits of human breast tumours.
C M Perou, T Sørlie, +15 authors, D Botstein.
Nature, 2000 Aug 30; 406(6797). PMID: 10963602
Highly Cited.
PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2.
G C Wishart, C D Bajdik, +34 authors, P D P Pharoah.
Br J Cancer, 2012 Aug 02; 107(5). PMID: 22850554    Free PMC article.
Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study.
Mitch Dowsett, Jack Cuzick, +11 authors, Steven Shak.
J Clin Oncol, 2010 Mar 10; 28(11). PMID: 20212256
Highly Cited.
A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors.
Martin Filipits, Margaretha Rudas, +25 authors, EP Investigators.
Clin Cancer Res, 2011 Aug 03; 17(18). PMID: 21807638
Highly Cited.
Gene expression profiling predicts clinical outcome of breast cancer.
Laura J van 't Veer, Hongyue Dai, +13 authors, Stephen H Friend.
Nature, 2002 Feb 02; 415(6871). PMID: 11823860
Highly Cited.
Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies.
Fiona M Blows, Kristy E Driver, +40 authors, David Huntsman.
PLoS Med, 2010 Jun 04; 7(5). PMID: 20520800    Free PMC article.
Highly Cited.
Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer.
Jack Cuzick, Mitch Dowsett, +10 authors, John F Forbes.
J Clin Oncol, 2011 Oct 13; 29(32). PMID: 21990413
Highly Cited.
The impact of primary tumor size, lymph node status, and other prognostic factors on the risk of cancer death.
L Leon Chen, Matthew E Nolan, +6 authors, James S Michaelson.
Cancer, 2009 Aug 07; 115(21). PMID: 19658184
Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.
William J Gradishar, Benjamin O Anderson, +28 authors, Rashmi Kumar.
J Natl Compr Canc Netw, 2016 Mar 10; 14(3). PMID: 26957618
Highly Cited.
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013.
A Goldhirsch, E P Winer, +5 authors, Panel members.
Ann Oncol, 2013 Aug 07; 24(9). PMID: 23917950    Free PMC article.
Highly Cited.
Identification of novel reference genes using multiplatform expression data and their validation for quantitative gene expression analysis.
Mi Jeong Kwon, Ensel Oh, +8 authors, Young Kee Shin.
PLoS One, 2009 Jul 09; 4(7). PMID: 19584937    Free PMC article.
BTN3A2 expression in epithelial ovarian cancer is associated with higher tumor infiltrating T cells and a better prognosis.
Cécile Le Page, Alexandre Marineau, +8 authors, Jean-François Cailhier.
PLoS One, 2012 Jun 12; 7(6). PMID: 22685580    Free PMC article.
A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer.
Torsten O Nielsen, Joel S Parker, +12 authors, Matthew J Ellis.
Clin Cancer Res, 2010 Sep 15; 16(21). PMID: 20837693    Free PMC article.
Highly Cited.
Confirmation of a prognostic index in primary breast cancer.
J H Todd, C Dowle, +5 authors, J L Haybittle.
Br J Cancer, 1987 Oct 01; 56(4). PMID: 3689666    Free PMC article.
Highly Cited.
Estrogen Receptor Expression in 21-Gene Recurrence Score Predicts Increased Late Recurrence for Estrogen-Positive/HER2-Negative Breast Cancer.
Mitch Dowsett, Ivana Sestak, +6 authors, Jack Cuzick.
Clin Cancer Res, 2015 Jun 17; 21(12). PMID: 26078431
Molecular biology in breast cancer: intrinsic subtypes and signaling pathways.
Pilar Eroles, Ana Bosch, J Alejandro Pérez-Fidalgo, Ana Lluch.
Cancer Treat Rev, 2011 Dec 20; 38(6). PMID: 22178455
Highly Cited. Review.
A prognostic index in primary breast cancer.
J L Haybittle, R W Blamey, +5 authors, K Griffiths.
Br J Cancer, 1982 Mar 01; 45(3). PMID: 7073932    Free PMC article.
Highly Cited.
Molecular portraits revealing the heterogeneity of breast tumor subtypes defined using immunohistochemistry markers.
Xiaofeng Dai, Yang Li, Zhonghu Bai, Xu-Qing Tang.
Sci Rep, 2015 Sep 26; 5. PMID: 26404658    Free PMC article.
A prognostic model for lymph node-negative breast cancer patients based on the integration of proliferation and immunity.
Ensel Oh, Yoon-La Choi, +3 authors, Young Kee Shin.
Breast Cancer Res Treat, 2011 Jun 15; 132(2). PMID: 21667120
A 3-gene proliferation score (TOP-FOX-67) can re-classify histological grade-2, ER-positive breast cancers into low- and high-risk prognostic categories.
Borbala Szekely, Takayuki Iwamoto, +7 authors, Lajos Pusztai.
Breast Cancer Res Treat, 2013 Mar 19; 138(3). PMID: 23504136
Converting a breast cancer microarray signature into a high-throughput diagnostic test.
Annuska M Glas, Arno Floore, +9 authors, Laura J Van't Veer.
BMC Genomics, 2006 Nov 01; 7. PMID: 17074082    Free PMC article.
Highly Cited.
Gene expression profiling of breast cancer: a new tumor marker.
Laura J van't Veer, Soonmyung Paik, Daniel F Hayes.
J Clin Oncol, 2005 Mar 10; 23(8). PMID: 15755970
Review.
Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population.
Dennis C Sgroi, Ivana Sestak, +9 authors, Mitch Dowsett.
Lancet Oncol, 2013 Sep 17; 14(11). PMID: 24035531    Free PMC article.
Highly Cited.
Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancer.
Karen J Taylor, Andrew H Sims, +8 authors, Simon P Langdon.
Breast Cancer Res, 2010 Jun 24; 12(3). PMID: 20569502    Free PMC article.
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
Triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival.
Yoon-La Choi, Ensel Oh, +12 authors, Young Kee Shin.
BMC Cancer, 2010 Sep 24; 10. PMID: 20860845    Free PMC article.
Identification of early molecular markers for breast cancer.
Céline Kretschmer, Anja Sterner-Kock, +3 authors, Wolfgang Kemmner.
Mol Cancer, 2011 Feb 15; 10(1). PMID: 21314937    Free PMC article.
Epidemiology of basal-like breast cancer.
Robert C Millikan, Beth Newman, +13 authors, Charles M Perou.
Breast Cancer Res Treat, 2007 Jun 21; 109(1). PMID: 17578664    Free PMC article.
Highly Cited.
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
Kathy S Albain, William E Barlow, +20 authors, Breast Cancer Intergroup of North America.
Lancet Oncol, 2009 Dec 17; 11(1). PMID: 20005174    Free PMC article.
Highly Cited.
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Lancet, 2005 May 17; 365(9472). PMID: 15894097
Highly Cited.
Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes.
Christine Desmedt, Benjamin Haibe-Kains, +6 authors, Christos Sotiriou.
Clin Cancer Res, 2008 Aug 14; 14(16). PMID: 18698033
Highly Cited.
BTF4/BTNA3.2 and GCS as candidate mRNA prognostic markers in epithelial ovarian cancer.
Cécile Le Page, Véronique Ouellet, +3 authors, Anne-Marie Mes-Masson.
Cancer Epidemiol Biomarkers Prev, 2008 Apr 10; 17(4). PMID: 18398031
Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen.
A Prat, J S Parker, +9 authors, C M Perou.
Ann Oncol, 2012 Apr 26; 23(11). PMID: 22532584    Free PMC article.
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.
T Sørlie, C M Perou, +14 authors, A L Børresen-Dale.
Proc Natl Acad Sci U S A, 2001 Sep 13; 98(19). PMID: 11553815    Free PMC article.
Highly Cited.
Annual hazard rates of recurrence for breast cancer after primary therapy.
T Saphner, D C Tormey, R Gray.
J Clin Oncol, 1996 Oct 01; 14(10). PMID: 8874335
Highly Cited.
The 70-gene prognostic signature for korean breast cancer patients.
Kuk Young Na, Ku Sang Kim, +7 authors, Yong Sik Jung.
J Breast Cancer, 2011 Aug 19; 14(1). PMID: 21847392    Free PMC article.
Toward the precision breast cancer survival prediction utilizing combined whole genome-wide expression and somatic mutation analysis.
Yifan Zhang, William Yang, +3 authors, Mary Qu Yang.
BMC Med Genomics, 2018 Nov 21; 11(Suppl 5). PMID: 30454048    Free PMC article.
BCT score predicts chemotherapy benefit in Asian patients with hormone receptor-positive, HER2-negative, lymph node-negative breast cancer.
Mi Jeong Kwon, Sae Byul Lee, +8 authors, Young Kee Shin.
PLoS One, 2018 Nov 22; 13(11). PMID: 30462685    Free PMC article.
Clinical Validation of BCT Scores With Prognostic Factors in Hormone Receptor-positive, HER2-negative Early Breast Cancer.
Jeeyeon Lee, Won Hwa Kim, +9 authors, Ho Yong Park.
In Vivo, 2019 Oct 31; 33(6). PMID: 31662548    Free PMC article.
UBE2C Overexpression Aggravates Patient Outcome by Promoting Estrogen-Dependent/Independent Cell Proliferation in Early Hormone Receptor-Positive and HER2-Negative Breast Cancer.
Yu-Jin Kim, Gyunghwa Lee, +4 authors, Young Kee Shin.
Front Oncol, 2020 Feb 11; 9. PMID: 32039034    Free PMC article.
A new clinical-genomic model to predict 10-year recurrence risk in primary operable breast cancer patients.
Tzu-Ting Huang, Lei Lei, +3 authors, Skye Hung-Chun Cheng.
Sci Rep, 2020 Mar 19; 10(1). PMID: 32184406    Free PMC article.
Comparison of GenesWell BCT Score With Oncotype DX Recurrence Score for Risk Classification in Asian Women With Hormone Receptor-Positive, HER2-Negative Early Breast Cancer.
Mi Jeong Kwon, Jeong Eon Lee, +12 authors, Young Kee Shin.
Front Oncol, 2019 Aug 14; 9. PMID: 31404265    Free PMC article.
Efficacy of an RNA-based multigene assay with core needle biopsy samples for risk evaluation in hormone-positive early breast cancer.
Jeeyeon Lee, Eun Hye Lee, +9 authors, Jin Hyang Jung.
BMC Cancer, 2019 Apr 27; 19(1). PMID: 31023265    Free PMC article.
A novel immune prognostic index for stratification of high-risk patients with early breast cancer.
Hannah Lee, Mi Jeong Kwon, +3 authors, Young Kee Shin.
Sci Rep, 2021 Jan 10; 11(1). PMID: 33420250    Free PMC article.
Recent Discoveries of Macromolecule- and Cell-Based Biomarkers and Therapeutic Implications in Breast Cancer.
Hsing-Ju Wu, Pei-Yi Chu.
Int J Mol Sci, 2021 Jan 14; 22(2). PMID: 33435254    Free PMC article.
Review.